The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats

International Journal of Pharmaceutics

Volumn 353, Issue 1-2, 2008, Pages 251-259

  Dadashzadeh, S ^a   Vali, A M ^a,b   Rezaei, M ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF ZANJAN   (Iran)

Author keywords

Conventional liposome; Cytotoxicity; PEGylated liposome; Pharmacokinetic; Stability; Topotecan

Indexed keywords

CHOLESTEROL; LACTONE; LIPOSOME; MACROGOL; TOPOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COATING; DRUG CYTOTOXICITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; ENCAPSULATION; FILM; HUMAN; HUMAN CELL; HYDRATION; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; WISTAR RAT; ZETA POTENTIAL;

EID: 40149103934     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.11.030     Document Type: Article

References (35)

1. S.A. Abraham K. Edwards G. Karlsson N. Hudon L.D. Mayer M.B. Bally An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes J. Control. Release 96 2004 449 461
2. T.M. Allen D.D. Stuart Liposome pharmacokinetics: classical, sterically stabilized, cationic liposomes and immunoliposomes A.S. Janoff Liposomes: Rational Design 1999 Marcel Dekkar New York 63 87
3. D.R. Arifin A.F. Palmer Physical properties and stability mechanisms of poly(ethylene glycol) conjugated liposome encapsulated hemoglobin dispersions Artif. Cells Blood Substit. Immobil. Biotechnol. 33 2005 137 162
4. M.B. Bally R. Nayar D. Masin M.J. Hope P.R. Cullis L.D. Mayer Liposomes with entrapped doxorubicin exhibit extended blood residency times Biochim. Biophys. Acta 1023 1990 133 139
5. T.G. Burke X. Gao Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine J. Pharm. Sci. 83 1994 967 969
6. C. Caserini G. Pratesi M. Tortoreto Apoptosis as a determinant of tumor sensitivity to TPT in human ovarian tumors: preclinical in vitro / in vivo studies Clin. Cancer Res. 3 1997 955 961
7. T. Daemen J. Regts M. Meesters M.T. Ten Kate I.A.J.M. Bakker-Woudenberg G.L. Scherphof Toxicity of doxorubicin entrapped within long-circulating liposomes J. Control. Release 44 1997 1 9
8. P. D’Arpa L.F. Liu Topoisomerase-targeting antitumor drugs Biochim. Biophys. Acta 989 1989 163 177
9. M.H. Gaber M.M. Ghannam S.A. Ali W.A. Khalil Interaction of Doxorubicin with phospholipid monolayer and liposomes Biophys. Chem. 70 1998 223 229
10. A. Gabizon Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes Cancer Res. 52 1992 891 896
11. A. Gabizon M. Chemla D. Tzemach A.T. Horowitz D. Goren Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines J. Drug Target 3 1996 391 398
12. A. Gabizon R. Isacson E. Libson B. Kaufman B. Uziely R. Catane Clinical studies of liposome encapsulated doxorubicin Acta Oncol. 33 1994 779 786
13. A. Gabizon F. Martin Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours Drugs 54 1997 15 21
14. Y.L. Hao Y.J. Deng Y. Chen K.Z. Wang A.J. Hao Y. Zhang In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan J. Pharm. Pharmacol. 57 2005 1279 1287
15. H. Harashima H. Kiwada Liposomal targeting and drug delivery: kinetic consideration Adv. Drug Deliv. Rev. 19 1996 425 444
16. R.P. Hertzberg M.J. Caranfa K.G. Holden Modification of the hydroxy lactone ring of camptothec: inhibition of mammalian topoisomerase I and biological activity J. Med. Chem. 32 1989 715 720
17. H. Hochster L. Liebes J. Speyer Phase I trial of low-dose continuous TPT infusion in patients with cancer: an active and well-tolerated regimen J. Clin. Oncol. 12 1994 553 559
18. M.J. Hope M.B. Bally G. Webb P.R. Cullis Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential Biochim. Biophys. Acta 812 1985 55 65
19. S.K. Huang K.D. Lee K. Hong D.S. Friend D. Papahadjopoulos Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice Cancer Res. 52 1992 5135 5143
20. W.D. Kingsbury J.C. Boehm D.R. Jakas Synthesis of water-soluble (aminoalkyl)-camptothecin analogues: inhibition of topoisomerase I and antitumor activity J. Med. Chem. 34 1991 98 107
21. D.D. Lasic F.J. Martin A. Gabizon S.K. Huang D. Papahadjopoulos Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times Biochim. Biophys. Acta 1070 1991 187 192
22. J.J. Liu R.L. Hong W.F. Cheng K. Hong F.H. Chang Y.L. Tseng Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation Anticancer Drugs 13 2002 709 717
23. A. Lorence C.L. Nessler Camptothecin, over four decades of surprising findings Phytochemistry 65 2004 2735 2749
24. F.J. Martin Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin) D.D. Lasic D. Papahadjopoulos Medical Applications of Liposomes 1998 Elsevier Science New York 635 688
25. D. Papahadjopoulos Steric stabilization an overview A.S. Janoff Liposomes Rational Design 1999 Marcel Dekker New York 1 12
26. D. Papahadjopoulos T.M. Allen A. Gabizon E. Mayhew K. Matthay S.K. Huang Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. U.S.A. 88 1991 11460 11464
27. L. Shargel S. Wu-Pong A.B.C. Yu Applied Biopharmaceutics and Pharmacokinetics fifth ed. 2005 Appleton & Lange Connecticut pp. 67–98
28. T. Siegal A. Horowitz A. Gabizon Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy J. Neurosurg. 83 1995 1029 1037
29. P. Tardi E. Choice D. Masin T. Redelmeier M.B. Bally T.D. Madden Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models Cancer Res. 60 2000 3389 3393
30. S. Unezaki K. Maruyama O. Ishida A. Suginaka J. Hosoda M. Iwatsuru Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipatic poly(ethylene glycol) Int. J. Pharm. 126 1995 41 48
31. A.M. Vali B. Shafaghi S. Dadashzadeh Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 818 2005 205 212
32. Vali, A.M., Toliyat, T., Shafaghi B., Dadashzadeh, S. Preparation, optimization and characterization of topotecan loaded PEGylated liposomes using factorial design. Drug Dev. Ind. Pharm., in press.
33. L.J. Van Warmerdam W.W. Ten Bokkel Huinink S. Rodenhuis I. Koier B.E. Davies H. Rosing Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion J. Clin. Oncol. 13 1995 1768 1776
34. M.S. Webb D. Saxon F.M. Wong H.J. Lim Z. Wang M.B. Bally Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine Biochim. Biophys. Acta 1372 1998 272 282
35. M.C. Woodle D.D. Lasic Sterically stabilized liposomes Biochim. Biophys. Acta 1113 1992 171 199